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Abstract
Background treatment of breast cancer as one of the most common cancers in the world remains an important area of drug
development based on nanoparticulate systems. Effective targeted therapy of affected cells based on ligand conjugate biocom-
patible polymeric nanoparticles is an attractive perspective in this context.
Objective In this study, a novel double effect nanoparticle based on Chitosan-Raloxifene conjugate was prepared for adjuvant
therapy (hormone and chemo therapy) and drug targeting to breast cancer cells via estrogen receptor (ER).
Methods Chitosan-raloxifene conjugate was synthesized. Related nanoparticles containing doxorubicin (DOX) were prepared
and characterized. Experimental design study was performed to determine the optimum levels of variables in the preparation of
nanoparticle. Drug loading, release, nanoparticle stability, and the effect of nanoparticles on cell viability were evaluated. Further,
inhibition tests were performed to demonstrate that the function of these novel nanoparticles is mediated via ER.
Results Chitosan-raloxifene conjugate was successfully synthesized. The prepared nanoparticles showed sizes within 25–35 nm,
more than 95% drug loading, about 60% of drug release and desired stability after 24 h. XTT assay onMCF-7 cell line illustrated
that these nanoparticles could inhibit the cellular growth up to 60%. The results from inhibition tests revealed that prepared
nanoparticles can inhibit cell growth via ER blocking.
Conclusion This study introduced chitosan-raloxifene nanoparticles containing doxorubicin as a novel targeting agent for adju-
vant therapy of breast cancer.
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Introduction
High toxicity of chemotherapeutic drugs in response to their
extensive distribution in both healthy and cancerous cells [1,
2] causes severe adverse effects. To overcome this problem,
attempts have been made to enhance the efficacy of drugs and
reduce their side effects through targeting delivery via nano-
particles (NPs) [3]. Biopolymeric NPs have a high potential to
be used as drug carriers. Among them, unique characteristics
of chitosan (CS) such as its cationic nature [4] which is based
on its primary amino groups, make its NPs one of the best
candidates for usage as targeting drug carriers [5, 6].
Furthermore, high affinity of CS for binding to negatively
charged biological membranes and some tumor cells contrib-
utes to site-specific targeting [7].
Specific targeting ligands such as folic acid [8], galactose [9]
and FAP-B [10] have been introduced to CS NPs in order to
synthesize an acceptable tumor specific drug carrier which can
target overexpressed tumor receptors or new specific ones [6].
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The first class of targeted therapy employed to treat breast
cancer is hormone therapy [11, 12]. Since nearly 70% of
breast cancers express the ER [11, 12], blocking its function
can reduce the risk of breast cancer progression. Selective
estrogen receptor modulators (SERMs) are synthetic com-
pounds that have agonist/antagonist activity depending on
the affected tissue [13, 14]. Raloxifene (RAL) is a second-
generation drug of SERMs which has an agonist function on
skeleton and cardiovascular system and antagonist effect on
uterus and breast [15–17]. Estrogen-dependent proliferation
of MCF-7 (human mammary tumor cells) can be inhibited
by RAL in vitro. Further, the growth of carcinogen-induced
mammary tumors in rats has been blocked via RAL [15].
Thus, by taking advantage of both CS NPs and RAL, a
unique delivery system can be developed for targeted breast
cancer therapy.
In this study, RAL-CS conjugate NPs (RC NPs) containing
DOX were prepared and characterized to be used as a new
double effect anticancer system for improving drug targeting
to breast cancer cells.
Materials and methods
Biological and chemical reagents
Trimethyl chitosan (TMC) (Low Molecular Weight,
deacetylation degree >90%) was kindly provided by pharma-
ceutical research laboratory of Tehran University of medical
science. Further, 3-Glycidyloxypropyltrimethoxysilane (3-
GPTMS) , doxo rub i c i n , T r i e t hy l am ine (E t 3N ) ,
T r i p o l y p h o s p h a t e ( T P P ) , s o d i u m
3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-
6-nitro) benzene sulfonic acid hydrate powder (XTT),
Phenazine methosulfate (PMS), dimethyl sulfoxide
(DMSO), and Penicillin-Streptomycin were purchased from
SigmaAldrich, (USA). Chemical solvents were obtained from
Merck, (Germany). Dulbecco’s modified eagle medium
(DMEM), Fetal Bovine Serum (FBS), and Trypsin-EDTA
were obtained from Gibco (Germany). Estradiol valerate
was purchased from Iran hormone company (Iran) and
Raloxifene HCL was also kindly provided by this company.
All chemical and biological materials were of pharmaceutical
grade.
Synthesis and characterization of RAL-CS conjugate
(RC conjugate)
Synthesis of RC conjugate was performed as previously de-
scribed by our group. Briefly, a mixture of RAL (50 mg) and
3-GPTMS as a linker (100 μl) was mixed together and stirred
under an argon atmosphere blanket at 60 °C for 30 min. Then,
DMF (1 ml) and Et3N (20 μl) were added to the resulting
mixture respectively and stirred for 24 h. The yellowish pre-
cipitated product (linker-RAL conjugate) was washed with
copious amounts of methanol to eliminate the excess of epoxy
linker. TMC hydrogel solution (7 ml, 1% (w/v)) was added to
the drug-linker mixture and stirred at room temperature for
24 h. Then, organic and aqueous phases were separated by
chloroform with the study continued using the aqueous phase.
To remove all residual reactants and unreacted linker/RAL,
the final mixture was dialyzed against sodium acetate buffer
(pH: 4.8–5) for 72 h. The final product was dried at 110 °C
and subjected to Fourier transform infrared spectroscopy
(FTIR) (Magna-IR 550 Nicolet FTIR spectrometer) and
Thermogravimetric analysis (TGA-50,Shimadzu) evaluations
as described elsewhere [6].
Preparation of RC NPs
A solution of TPP was prepared in distilled water (1 mg/ml)
and RC solution (0.44 mg/ml) in a mixture of solvents (TFA/
DMSO ratio 27:1). CS NPs were formed through dropwise
addition of RC solution to TPP solution under magnetic stir-
ring (20 min). Various formulations at different TPP to RC
weight ratios were prepared (Table 1). After adjusting the pH
(=5) using NaOH 1 N, the particle size and zeta potential of
NPs were measured.
Preparation of DOX loaded RCNPs (DRC NPs)
The best TPP/RC weight ratios (based on size and zeta poten-
tial results) were used to prepare DRC NPs. Briefly, a solution
of DOX in water (0.875 mg/ml) was added to RC at a final
concentration of 5% (w/w) in relation to RC.
Experimental design study
The optimum levels of variables in NPs preparation were de-
termined via Box-Behnken design which is the most accepted
response surface methodology (RSM). RSM allows estima-
tion of the parameters of a quadratic model which requires
fewer runs in case of three variables [18].
Box-Behnken design was employed to study all princi-
pal effective factors (independent variables) and to assess
which factor affects the responses (dependent variables).
Table 1 TPP/RC weight
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In this design, 3 factors were examined in 15 trials at high
and low levels. Design-Expert (version 7.0.0; Stat-Ease,
Inc., Minneapolis, Minnesota, USA) was employed for
mathematical modeling and assessment of the responses.
The pH of the solution (X1), DOX/RC weight ratio (X2),
and TPP/RC weight ratio (X3) were analyzed at two levels. Y1
and Y2 were studied as responses including particle size and
zeta potential respectively. In this design, 12 factorial points
with 3 replicates were studied at the central point for calcula-
tion of pure error sum of squares.
The mathematical relationship between the response (Y1)
and independent variables (X1, X2, X3) is presented in Eq. 1:
Y1 ¼ 28:27
þ 5:65 X1−180 X2−180 X3−64:27 X1X2−7:11 X1X3
þ 180 X2X3−13:26 X12 þ 159:62 X22−7:89 X32
þ 115:73 X12 X2 þ 174:35 X12 X3
þ 168:98 X1 X22
ð1Þ
According to the responses generated from mathematical
formula, two formulations called a1 and a2 (Table 2) were
selected to continue the study.
NPs were prepared by these formulations and used for cy-
totoxicity assay as well as inhibition tests.
Particle size analysis and zeta potential measurement
Size distribution and zeta potential of the NPs were measured
using a Zetasizer (Nano ZSP, Malvern Instruments, UK), with
a red laser of wavelength λ0 = 633 nm (He-Ne, 4.0 Mw). The
analysis was performed in triplicate at a temperature of 25 °C.
Transmission electron microscopy (TEM)
The surface morphological analysis of DRC NPs was carried
out via transmission electron microscopy (TEM, Zeiss
EM10C, Germany operating at 100 kv). The suspension of
NPs was dropped onto formvar carbon coated grid Cu Mesh
300 and dried at room temperature.
DOX loading efficiency
The loading efficiency was calculated according to Eq. (2),
where the total DOX refers to the concentration of DOX used
in the preparation of nanoparticles while free DOX denotes
the concentration of the supernatant after ultracentrifugation
of loaded nanoparticles at 14000×g for 10 min using centrif-
ugal filter units (30 K, Amicon®, EMD Millipore Co., 152
MA, USA).




One milliliter of nanoparticle solution was sealed in a dialysis
tube (molecular weight cutoff of 12,000–14,000 g/mol) and
immersed in 50 ml PBS (pH 7.4) at 37°C for 24 h with a
continuous stirring. At predetermined times, an aliquot (1 ml
each) was withdrawn and the same volume of fresh medium
was added. The concentration of DOX was measured based
on the absorbance of DOX at 480 nm using UV- spectropho-
tometer (2100 Unico, USA).
Stability study
For assessing the stability of DRC NPs, they were diluted in
10 mM PBS (pH 7.4) at 50 mg/ml and placed in an incubator
maintained at 37 °C for 72 h. At predetermined times (0, 3, 6,
12, 24, 48, and 72 h), samples were withdrawn and the particle
size and zeta potential of the samples determined as described
above.
Cell culture
Human breast cancer cell line (MCF-7) was obtained from
National Cell Bank of Iran (the Pasteur Institute of Iran,
Tehran). The cells were cultured in DMEM media supple-
mented with 10% (v/v) FBS and 1% Penicillin-Streptomycin
at 37 °C in an incubator with 5% CO2.
This was done according to the procedures approved by the
Ethics committee of Avicenna Research Institute (ethics code:
92/933).
Assessment of cytotoxicity
One of the most common methods to evaluating the cell via-
bility, cell proliferation and/or cytotoxicity is XTT assay. This
method is based on color changes upon the reduction of slight-
ly yellow XTT powder (tetrazolium salt) to its orange
formazan derivative. In this study, to evaluate the cytotoxicity
of NPs, XTT assay was utilized. In brief, MCF-7 cells were
seeded in a flat 96-well culture plate (104 cells per well) and
Table 2 Selected formulations according to experimental design
responses
Formulation code pH TPP/RC weight ratio DOX/RC weight ratio
a1 5.69 23.34 7.35
a2 4.62 30.36 12.07
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kept in an incubator (37 °C, 5% CO2) to attach to plate. After
24 h, the culture medium was discarded and fresh DMEM
(phenol red free) was replaced. According to Table 3, different
concentrations of NPs were added to each well in triplicates
and then incubated for 24 h. To compare the effect of NPs,
culture medium and solvents were considered as controls.
XTT and PMS solutions were prepared by dissolving XTT
powder in a pre-warmed medium (1 mg/ml) and the PMS in
phosphate buffered saline (1.53 mg/ml) respectively.
Effective reduction of XTT occurs in the presence of an elec-
tron coupling agent such as PMS (phenazine methosulfate).
Here, 5 μl PMS solution was added to 1 ml XTT solution
and then 50 μl of this mixture was added to each well and
incubated for 2–4 h at 37 °C, 5%CO2. Finally, the absorbance
of samples was measured at a wavelength of 450 nm, using a
photometer (ELISA reader, BioTek).
Inhibition tests
Inhibition tests on MCF-7 cells were done by two methods as
below:
One-step method
The MCF-7 cells were seeded in a 96-well plate at a
density of 104 cells/well in DMEM supplemented with
10% FBS and 1% Penicillin-Streptomycin and kept in
incubator (37 °C, 5% CO2) to attach. After 24 h, the cells
were treated by samples (Table 4) and incubated under the
previously mentioned condition for another 24 h. The cul-
ture medium and mixture of media and solvent were con-
sidered as controls. Then, 50 μl of mixed XTT solution
(XTT + PMS) was added to each well with the test con-
tinuing as described in part 2.12.
Two-step method
The cells were seeded in a 96-well plate (104 cells/well). Then,
estradiol (10−8 M) was added to each well. The plates were
incubated for 24 h at 37 °C in an incubator with 5% CO2.
Then, the cells were treated by 50 μl of samples (Table 3)
for 24 h. Finally, the XTT assay was performed as described
previously.
Statistical analysis
The tests were repeated three times with the data being report-
ed as mean ± SD. Statistical analysis was performed using
Student’s t test where the level of statistical significance was
considered P < 0.05.
Results
FTIR studies
Figure 1 represents the IR spectra of TMC, RAL, linker, link-
er-RAL, and RC conjugate. According to Fig. 1-IId, IR spec-
trum of RC conjugate presented the expected characteristic
bands of RAL (3143 and 3205 cm−1) and TMC (1634, and
3431 cm−1).
TGA studies
Figure 2 displays the studies on the thermal behavior of
the TMC, RAL, and RC conjugate by TGA. The resulting
thermograms are according to our previous published data
Table 4 Sample codes and their descriptions for inhibition test (one-
step method)
Sample codes Description
a1 DRC NPs, TPP/RC: 23.34
a2 DRC NPs, TPP/RC: 30.36
b1 a1 without DOX
b2 a2 without DOX
c1 TMC NPs, TPP/TMC: 23.34
c2 TMC NPs, TPP/TMC: 30.36
m1 a1 + (estradiol in ethanol, 10
−8 M)
m2 a2 + (estradiol in ethanol, 10
−8 M)
n1 b1 + (estradiol in ethanol, 10
−8 M)
n2 b2 + (estradiol in ethanol, 10
−8 M)
p1 c1 + (estradiol in ethanol, 10
−8 M)
p2 c2 + (estradiol in ethanol, 10
−8 M)
Table 3 Sample codes and their descriptions for cytotoxicity and
inhibition (two-step method) tests
Sample codes Description
a1 DRC NPs, TPP/RC: 23.34
a2 DRC NPs, TPP/RC: 30.36
b1 a1 without DOX
b2 a2 without DOX
c1 TMC NPs, TPP/TMC: 23.34
c2 TMC NPs, TPP/TMC: 30.36
d1 RC conjugate at concentration which used in a1
d2 RC conjugate at concentration which used in a2
e1 TMC at concentration which used in a1
e2 TMC at concentration which used in a2
f1 DOX at concentration which used in a1
f2 DOX at concentration which used in a2
g1 RAL at concentration which used in a1
g2 RAL at concentration which used in a2
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Fig. 1 IR Spectra of I) TMC, II) a) RAL, b) linker, c) linker-RAL, d) RC conjugate
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[6]. The thermogram of RC conjugate showed that there is
only one-step degradation from 231.05 °C to 325.77 °C
with 61.15% weight loss. The start point of this decom-
position is approximately between the main decomposi-
tion start points of RAL (298 °C) and TMC (201 °C).
This pattern is observed in case of decomposition end
points (RAL: 351.68 °C, TMC: 274 °C and RC conjugate:
325.77 °C).
Preparation and physical evaluations of NPs
Among CSNPs preparationmethods, ionic gelation technique
is the most attractive method because of non-toxicity due to
lack of organic solvents, simplicity, and controllability [19,
20]. The formation of CS NPs is based on electrostatic inter-
action between the amine group of CS and negatively charged
polyanion such as TPP [19–21].
The zeta potential and size distribution of two selected
formulations were measured using Nano ZSP. The results
indicated that the sizes of two selected formulations (accord-
ing to experimental design studies), a1 and a2, were 34.75 ±
2.1 nm and 26.85 ± 1.89 nm respectively (PDI = 0.3 ± 0.05).
In addition, their zeta potentials were 0.17 ± 0.02 mv (a1) and
− 0.49 ± 0.04 mv (a2) (width = 4.5 ± 1).
The morphological observation of NPs using TEM re-
vealed spherical/cylindrical NPs with homogeneous dispersity
(Fig. 3).
Loading, release, and stability studies
The loading efficiency of the selected nanoparticles was cal-
culated according to Eq. 2. Dox loading in formulations a1 and
a2 was 98% ± 2% and 95% ± 4% respectively.
The in-vitro cumulative release profiles of DRC nanopar-
ticles in both a1 and a2 formulations displayed a similar release
pattern, indicating that almost 60% of Dox was released after
24 h (Fig. 4a).
On the other hand, Dox was rapidly released from nano-
particles; nearly 30% of the incorporated Dox was released
within 2 h.
The physical stabilities of the nanoparticles suspended in
PBS (pH 7.4) were evaluated over 3 days at 37 °C. As shown
in Fig. 4b, c, the particle sizes and zeta potentials of both
formulations were maintained well for a day. However, after
24 h, the size of nanoparticles increased gradually, which can
be due to particle aggregation. Furthermore, the zeta potentials
of both formulations were changed after 24 h.
Cytotoxicity studies
The results obtained from cytotoxicity assay (Fig. 5a) indicat-
ed that cytotoxicity of RC NPs at a weight ratio of RC/TPP:
30.36 (b2) was about 60% which is significantly more than
that of TMCNPs at the same ratio (c2). On the other hand, the
intact polymeric RC (d1, d2) showed no toxicity on cells.
Fig. 2 Thermogram of TMC, RAL and RC conjugate
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In addition, DRC NPs (a1, a2) led to a significantly lower




In this study, NPs were designed to target ER. Thus, this
receptor at the surface of MCF-7 cells was blocked by estra-
diol as the main ligand.
Accordingly, estradiol and prepared NPs were added to
culture medium simultaneously (according to Table 4 to
evaluate their effects on cell death). The results indicated
that with estradiol and NPs added to media (m1), cell
growth inhibition decreased significantly compared to ab-
sence of estradiol (a1).
Particularly, a greater reduction in cell growth inhibi-
tion was observed when the TPP/RC weight ratio in-
creased (m2 compared to m1). On the other hand, in case
of TMC NPs, in the presence of estradiol at both weight
ratios (p1 and p2), no significant reduction in inhibition
effect was observed when compared to absence of estra-
diol (c1 and c2) (Fig. 5b).
Two-step method
To confirm the results obtained from one-step method of
inhibition test, the second method was carried out. In
this method, estradiol as a cell growth inducer for
MCF-7 cells (due to the existence of ER on these cells
surfaces) was initially added to the culture medium (24 h
prior to treatment). The obtained results (Fig. 5c) indi-
cated that DRC NPs (a1, a2) as compared to TMC NPs
(c1, c2), had significantly greater inhibitory effects on
cell growth.
Discussion
The ability of chitosan to conjugate with specific targeting
agents makes its nanoparticles very effective vehicles for de-
livery of chemotherapeutic drugs to tumor cells. As most
breast cancers express ER, molecules with an antagonist effect
on this receptor such as RAL can reduce the risk of breast
cancer by blocking the ER function. Thus, in this study,
chitosan-raloxifene nanoparticles containing doxorubicin
were prepared as a new double effect vehicle for drug
targeting to breast cancer cells.
Fig. 3 TEM photomicrograph of
DRC NPs
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After successful conjugation of RAL to TMC, their nano-
particles containing DOX were prepared. The pH of the solu-
tion, DOX/RC weight ratio, and TPP/RC weight ratio were
the most important independent variables affecting the size
and zeta potential of nanoparticles.
The best TPP/RC ratios in the nanoparticle formation se-
lected by experimental design study (a1:23.34 and a2:30.36)
showed desirable physical, morphological, and biological
characteristics.
Fig. 4 a In vitro release profiles
of doxorubicin from RC NPs; b
and c Stability profiles of DOX
loaded RCNPs in PBS (pH 7.4) at
37 °C. Values are shown as mean
± SD; n = 3
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The selected nanoparticles (formulations a1 and a2) showed
small sizes and small values of zeta potentials. These near-zero
zeta potentials could lead to particle aggregation and thus
formulation instability, which was observed after 24 h of stability
study.
Other researchers have also shown that different factors
can affect the size and zeta potential of chitosan nanopar-
ticles. Using experimental design study, Abdel-Hafez
et al. described that the optimum levels of pH, stirring
rate, acetic acid concentration, and CS:TPP ratio can lead
to small and mono-dispersed chitosan nanoparticles [18].
Some researchers found that the ratio of chitosan to other
polymeric/small molecules, which contributes to nanopar-
ticle formation, is very critical in producing the best nano-
particles [19–21].
The cytotoxicity of selected nanoparticles was assessed via
XTT assay on MCF-7 cells (Fig. 5a). It was found that the
presence of RAL in NPs structure (b2) could considerably
increase the cytotoxicity in comparison with TMC NPs (c2).
Cytotoxicity results showed that polymeric RC cannot medi-
ate cell toxicity; however, its nanoparticles can lead to cell
death clearly. This result can be due to an increase in the
effective area of NPs compared to intact RC, which can con-
sequently increase the probability of cell contact and cell
penetration.
As indicated, the cytotoxicity of free DOXwas greater than
that of DRC NPs. Strong and complete trapping of DOX
inside a1 and a2 nanoparticles (more than 95% loading effi-
ciency) and lack of complete release over the 24-h period
(about 60%) may lead to this observation. Further, DOX and
RAL can develop hydrogen bonding via OH/NH2 groups and
static π-π bonding moieties through aromatic rings in their
molecular structure, which may lead to unavailability of bio-
active parts of DOX thus lowering its biological effects.
Interestingly, Janes et al. obtained similar results about
chitosan-DOX nanoparticles and free DOX.When they found
that free DOX has greater cytotoxicity than DOX loaded chi-
tosan nanoparticles, they concluded that this may be attributed
to two reasons: drug-chitosan tight interaction and/or partial
damage to the molecular structure of DOX during its com-
plexation with chitosan [21].
Inhibition experiments were performed using twomethods.
In the first method, one step, the target receptor at the cell
surface was blocked using the free ligand and then the cells
Fig. 5 a Effect of DOX, RAL, RC conjugate, RC NPs and DRC NPs at
different concentrations on inhibition of MCF-7 cells growth (sample
definition is according to Table 3). Values are shown as mean ± SD;
n = 3. Statistical analysis was performed using Student’s t test, P < 0.05
bCytotoxicity effects of various samples onMCF-7 cells during one-step
method of inhibition test (sample definition is according to Table 4).
Values are shown as mean ± SD; n = 3. Statistical analysis was performed
using Student’s t test, P < 0.05. c cytotoxicity effects of various samples
on MCF-7 cells during two-step method of inhibition test (sample
definition is according to Table 3). Values are shown as mean ± SD;
n = 3. Statistical analysis was performed using Student’s t test, P < 0.05
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were treated by the prepared nanoparticulate delivery system.
It was expected that NPs would not be able to perform their
functions after blocking the receptors as strongly as before.
The obtained results indicated that the main effect of RC NPs
containing DOX on breast cancer cells is exerted through the
estrogen receptor. This conclusion is due to ER’s occupation
by estradiol causing inability of RC NPs to play its role.
However, under the same conditions, the cytotoxicity effect of
TMC nanoparticles was not reduced, which confirms this
mechanism.
In the second method of inhibition experiment, two step,
when cells were growing in the presence of estrogen (24 h prior
to the experiment), adding RAL (as an estrogen receptor blocker
present in a1 and a2 NPs) to the medium led to a competition
between these molecules; consequently, cell death increased via
blocking some ER receptors by RAL during this competition.
Thus, it seems that the prepared nanoparticles could block
estrogen receptors at the surface of the cancerous cells, and after
releasing doxorubicin, they could lead to targeted toxicity.
Conclusions
Overall, it was observed that this novel delivery system can be
used both as a targeted delivery system for ER+ breast cancer
cells (via estrogen receptor) and as a double effect system for
both chemo and hormone therapy. The results obtained from
this study confirmed that RC NPs containing DOX can be
applied in in-vivo studies as a potential cancer therapy system
in future.
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